Stock BRM BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bristol-Myers Squibb Company BOERSE MUENCHEN

Equities

BRM

US1101221083

Market Closed - BOERSE MUENCHEN
Other stock markets
 03:44:10 2024-07-11 pm EDT 		5-day change 1st Jan Change
37.48 EUR -1.43% Intraday chart for Bristol-Myers Squibb Company +1.54% -18.24%
Jul. 11 Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating MT
Jul. 10 Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43 MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company appears highly valued given the size of its balance sheet.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-18.24% 83.35B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+60.25% 846B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.56% 628B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.49% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.30% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.64% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.15% 240B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+3.11% 224B
A+
NOVARTIS AG Stock Novartis AG
+16.98% 223B
B-
AMGEN INC. Stock Amgen Inc.
+12.87% 173B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BRM Stock
  5. Ratings Bristol-Myers Squibb Company